REALM-DCM: a phase 3, multinational, randomized, placebo-controlled study of ARRY-371797 (PF-07265803) in patients with symptomatic LMNA-related dilated cardiomyopathy
Short-term changes in hemoglobin and changes in functional status, quality of life, and natriuretic peptides after initiation of dapagliflozin in heart failure with reduced ejection fraction
Speaker:
Doctor M. Amiguet Comins (Castellon de la Plana, ES)